<DOC>
	<DOC>NCT01289054</DOC>
	<brief_summary>This is a voluntary, international, primarily prospective, observational, exposure-registry and follow-up study of women receiving Imatinib and Nilotinib during pregnancy or within six months prior to pregnancy.</brief_summary>
	<brief_title>A Global Imatinib and Nilotinib Pregnancy Exposure Registry</brief_title>
	<detailed_description />
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Provide sufficient evidence to confirm that exposure occurred during pregnancy or within 6 months prior to exposure. Be at least 18 years of age Reside in a country supported by the Registry Cases that do not meet the eligibility criteria are deemed ineligible, including paternal exposures Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Female</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Hematologic Pregnancy</keyword>
	<keyword>Complications</keyword>
	<keyword>Registry</keyword>
	<keyword>Pregnant Registry</keyword>
	<keyword>CML</keyword>
	<keyword>GIST</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Tasigna</keyword>
	<keyword>Glivec</keyword>
	<keyword>Pregnancy Exposure</keyword>
</DOC>